Literature DB >> 22184389

From mitochondrial biology to magic bullet: navitoclax disarms BCL-2 in chronic lymphocytic leukemia.

Loren D Walensky1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22184389      PMCID： PMC4879972          DOI： 10.1200/JCO.2011.37.9339

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  26 in total

1.  Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function.

Authors:  Lin Chen; Simon N Willis; Andrew Wei; Brian J Smith; Jamie I Fletcher; Mark G Hinds; Peter M Colman; Catherine L Day; Jerry M Adams; David C S Huang
Journal:  Mol Cell       Date:  2005-02-04       Impact factor: 17.970

2.  Bcl-2 family proteins are essential for platelet survival.

Authors:  H Zhang; P M Nimmer; S K Tahir; J Chen; R M Fryer; K R Hahn; L A Iciek; S J Morgan; M C Nasarre; R Nelson; L C Preusser; G A Reinhart; M L Smith; S H Rosenberg; S W Elmore; C Tse
Journal:  Cell Death Differ       Date:  2007-01-05       Impact factor: 15.828

3.  Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia.

Authors:  Marina Konopleva; Rooha Contractor; Twee Tsao; Ismael Samudio; Peter P Ruvolo; Shinichi Kitada; Xingming Deng; Dayong Zhai; Yue-Xi Shi; Thomas Sneed; Monique Verhaegen; Maria Soengas; Vivian R Ruvolo; Teresa McQueen; Wendy D Schober; Julie C Watt; Tilahun Jiffar; Xiaoyang Ling; Frank C Marini; David Harris; Martin Dietrich; Zeev Estrov; James McCubrey; W Stratford May; John C Reed; Michael Andreeff
Journal:  Cancer Cell       Date:  2006-11       Impact factor: 31.743

4.  A stapled BID BH3 helix directly binds and activates BAX.

Authors:  Loren D Walensky; Kenneth Pitter; Joel Morash; Kyoung Joon Oh; Scott Barbuto; Jill Fisher; Eric Smith; Gregory L Verdine; Stanley J Korsmeyer
Journal:  Mol Cell       Date:  2006-10-20       Impact factor: 17.970

5.  Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors.

Authors:  Leena Gandhi; D Ross Camidge; Moacyr Ribeiro de Oliveira; Philip Bonomi; David Gandara; Divis Khaira; Christine L Hann; Evelyn M McKeegan; Elizabeth Litvinovich; Philip M Hemken; Caroline Dive; Sari H Enschede; Cathy Nolan; Yi-Lin Chiu; Todd Busman; Hao Xiong; Andrew P Krivoshik; Rod Humerickhouse; Geoffrey I Shapiro; Charles M Rudin
Journal:  J Clin Oncol       Date:  2011-01-31       Impact factor: 44.544

6.  Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis.

Authors:  Mai Nguyen; Richard C Marcellus; Anne Roulston; Mark Watson; Lucile Serfass; S R Murthy Madiraju; Daniel Goulet; Jean Viallet; Laurent Bélec; Xavier Billot; Stephane Acoca; Enrico Purisima; Adrian Wiegmans; Leonie Cluse; Ricky W Johnstone; Pierre Beauparlant; Gordon C Shore
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-26       Impact factor: 11.205

7.  AT-101, a pan-Bcl-2 inhibitor, leads to radiosensitization of non-small cell lung cancer.

Authors:  Luigi Moretti; Bo Li; Kwang Woon Kim; Heidi Chen; Bo Lu
Journal:  J Thorac Oncol       Date:  2010-05       Impact factor: 15.609

8.  ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor.

Authors:  Christin Tse; Alexander R Shoemaker; Jessica Adickes; Mark G Anderson; Jun Chen; Sha Jin; Eric F Johnson; Kennan C Marsh; Michael J Mitten; Paul Nimmer; Lisa Roberts; Stephen K Tahir; Yu Xiao; Xiufen Yang; Haichao Zhang; Stephen Fesik; Saul H Rosenberg; Steven W Elmore
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

9.  Mutagenesis of the BH3 domain of BAX identifies residues critical for dimerization and killing.

Authors:  K Wang; A Gross; G Waksman; S J Korsmeyer
Journal:  Mol Cell Biol       Date:  1998-10       Impact factor: 4.272

10.  The MCL-1 BH3 helix is an exclusive MCL-1 inhibitor and apoptosis sensitizer.

Authors:  Michelle L Stewart; Emiko Fire; Amy E Keating; Loren D Walensky
Journal:  Nat Chem Biol       Date:  2010-06-20       Impact factor: 15.040
View more
  18 in total

1.  Selectively targeting Mcl-1 for the treatment of acute myelogenous leukemia and solid tumors.

Authors:  Gregory J Gores; Scott H Kaufmann
Journal:  Genes Dev       Date:  2012-02-15       Impact factor: 11.361

2.  Cancer therapeutics: Pulling the plug on BCL-X(L).

Authors:  Paul S Jeng; Emily H Cheng
Journal:  Nat Chem Biol       Date:  2013-06       Impact factor: 15.040

3.  Selective targeting of JAK/STAT signaling is potentiated by Bcl-xL blockade in IL-2-dependent adult T-cell leukemia.

Authors:  Meili Zhang; Lesley A Mathews Griner; Wei Ju; Damien Y Duveau; Rajarshi Guha; Michael N Petrus; Bernard Wen; Michiyuki Maeda; Paul Shinn; Marc Ferrer; Kevin D Conlon; Richard N Bamford; John J O'Shea; Craig J Thomas; Thomas A Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  2015-09-22       Impact factor: 11.205

4.  Direct and selective small-molecule activation of proapoptotic BAX.

Authors:  Evripidis Gavathiotis; Denis E Reyna; Joseph A Bellairs; Elizaveta S Leshchiner; Loren D Walensky
Journal:  Nat Chem Biol       Date:  2012-05-27       Impact factor: 15.040

5.  Mcl-1 Phosphorylation defines ABT-737 resistance that can be overcome by increased NOXA expression in leukemic B cells.

Authors:  Suparna Mazumder; Gaurav S Choudhary; Sayer Al-Harbi; Alexandru Almasan
Journal:  Cancer Res       Date:  2012-04-23       Impact factor: 12.701

6.  Therapeutic effects of deleting cancer-associated fibroblasts in cholangiocarcinoma.

Authors:  Joachim C Mertens; Christian D Fingas; John D Christensen; Rory L Smoot; Steven F Bronk; Nathan W Werneburg; Michael P Gustafson; Allan B Dietz; Lewis R Roberts; Alphonse E Sirica; Gregory J Gores
Journal:  Cancer Res       Date:  2012-12-05       Impact factor: 12.701

7.  Proteasome inhibitors evoke latent tumor suppression programs in pro-B MLL leukemias through MLL-AF4.

Authors:  Han Liu; Todd D Westergard; Amanda Cashen; David R Piwnica-Worms; Lori Kunkle; Ravi Vij; Can G Pham; John DiPersio; Emily H Cheng; James J Hsieh
Journal:  Cancer Cell       Date:  2014-04-14       Impact factor: 31.743

8.  Effect of a Smac Mimetic (TL32711, Birinapant) on the Apoptotic Program and Apoptosis Biomarkers Examined with Validated Multiplex Immunoassays Fit for Clinical Use.

Authors:  Apurva K Srivastava; Soumya Jaganathan; Laurie Stephen; Melinda G Hollingshead; Adam Layhee; Eric Damour; Jeevan Prasaad Govindharajulu; Jennifer Donohue; Dominic Esposito; James P Mapes; Robert J Kinders; Naoko Takebe; Joseph E Tomaszewski; Shivaani Kummar; James H Doroshow; Ralph E Parchment
Journal:  Clin Cancer Res       Date:  2015-10-07       Impact factor: 12.531

Review 9.  Apoptosis and necrosis in the liver.

Authors:  Maria Eugenia Guicciardi; Harmeet Malhi; Justin L Mott; Gregory J Gores
Journal:  Compr Physiol       Date:  2013-04       Impact factor: 9.090

Review 10.  From modules to medicine: How modular domains and their associated networks can enable personalized medicine.

Authors:  Eric B Haura
Journal:  FEBS Lett       Date:  2012-05-07       Impact factor: 4.124
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.